British pharmaceutical firm BTG has announced the arrival of a new treatment for varicose veins.
The company's product, Varithena, offers a minimally invasive treatment that is capable of dissolving the veins without the need for surgery.
Varithena has received the FDA approval and should be available in the market in the second quarter of 2014.
This new treatment which targets both the symptoms and appearance of varicose veins employs injectible foam to dissolve the veins.
The company's chief executive Louise Makin said, "We look forward to the commercial U.S. launch in the second quarter of 2014, and to continuing to advance our plans to expand use into other geographies and into non-symptomatic veins."